Diroximel fumarate confers neuroprotection via reduced Th1 responses and induction of the anti-oxidative Nrf2 pathway in experimental neuroinflammation

David Freudenstein, Anna Schneeweiss, Adriana Krenz, Ralf Gold, Ralf Linker, Stefanie Haase · 2026

Read Diroximel fumarate confers neuroprotection via reduced Th1 responses and induction of the anti-oxidative Nrf2 pathway in experimental neuroinflammation by David Freudenstein, Anna Schneeweiss, Adriana Krenz, Ralf Gold, Ralf Linker, Stefanie Haase (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0355936.txt.

Description

David Freudenstein and five colleagues investigate how an approved multiple sclerosis drug protects nerve tissue, in this 2026 mouse study. The drug, diroximel fumarate, is related to a widely used treatment whose immune and antioxidant actions are only partly understood. The team gave it orally to mice with an induced autoimmune disease that mimics MS, then scored symptoms and examined spinal cord tissue, immune cells, and gene activity.

Treated mice fared markedly better clinically. Fewer immune cells invaded the spinal cord, particularly the aggressive Th1 type, myelin and nerve fibers were better preserved, and blood immune cells produced less of two inflammatory signals. Genes in a key antioxidant defense pathway switched on in central nervous tissue. The authors conclude the drug combines immune calming with antioxidant protection, supporting its benefit in neuroinflammation.

Catalog record

CREATORDavid Freudenstein, Anna Schneeweiss, Adriana Krenz, Ralf Gold, Ralf Linker, Stefanie Haase
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35210
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0355936

Browse the full library · About the Tower of Babel